BIOVIE BIVI 深 沪
已收盘 12-19 16:00:00 美东时间
1.4145
-0.035
-2.45%
华盛通- 最 高1.70
- 今 开1.43
- 成交量 4.80万股
- 最 低 1.33
- 昨 收 1.45
- 总市值 3534.00万
- 52周最高 9.56
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 0.62
- 委 比 96.36%
- 总股本 2498.41万
- 历史最高 46.098
- 量 比 0.93
- 振 幅 25.52%
- 历史最低 0.2506
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock increased by 16.8% to $0....
2024-09-27 04:31
Crude Oil Gains Over 1%; BioVie Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index ed...
2024-09-25 02:08
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2024-09-25 00:42
Why BioVie (BIVI) Stock Is Down Over 50% Today
BioVie shares are trading lower by 53% during Tuesday's session. The company announced it raised $3 million through a secondary offering.
2024-09-25 00:20
Dow Rises Over 50 Points; AutoZone Posts Downbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more t...
2024-09-24 21:41
Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket
Shares of Maison Solutions Inc. (NASDAQ:MSS) rose sharply in today's pre-market...
2024-09-24 17:40
Reported Earlier, BioVie Raised $3M VIa Secondary Stock Offering Of 1.96M Shares At $1.53/Share
BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and
2024-09-24 14:57
BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment
12:40 PM EDT, 09/03/2024 (MT Newswires) -- BioVie (BIVI) said Tuesday the US Food and Drug Administration has authorized its investigational new drug application to evaluate bezisterim for treating neurological symptoms associated with long COVID. The approval allows BioVie to proceed with a phase 2...
2024-09-04 00:40
